NCT01323998View on ClinicalTrials.gov

Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan

CompletedOBSERVATIONAL

Enrollment

35,032

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions

Prostatic Hyperplasia

Interventions

DRUG

5ARI

Dutasteride or Finasteride

DRUG

AB

Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01323998 - Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan | Biotech Hunter | Biotech Hunter